Chimeric receptor molecules for delivery of co-stimulatory signals

• US 5,712,149 A
• Filed: 02/03/1995
• Issued: 01/27/1998
• Est. Priority Date: 02/03/1995
• Status: Expired due to Term

• Current Assignee: BioSante Pharmaceuticals, Inc.
• Original Assignee: Cell Genesys Incorporated (ANI Pharmaceuticals, Inc.)
• Inventors: Roberts, Margo R.
• Primary Examiner(s): ULM, JOHN D
• Application Number:
  US08/383,749
• Time in Patent Office: 1,089 Days
• Field of Search: 435/64.7, 435/252.3, 435/320.1, 530/350, 536/23.4
• US Class Current: 435/252.3
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/55 IL-2
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 14/70507 CD2
• CPC Class Codes: C07K 14/7051 T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 14/70514 CD4
• CPC Class Codes: C07K 14/70521 CD28, CD152
• CPC Class Codes: C07K 14/70528 CD58
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

The present invention is directed to novel chimeric co-stimulatory receptor proteins and DNA sequences encoding these proteins. The chimeric receptors comprise at least three domains in a single chain molecule: an extracellular ligand binding domain, a transmembrane domain and a cytoplasmic co-stimulatory effector function signaling domain that acts synergistically with an effector function signal in the host cell. Novel hybrid co-stimulatory receptor proteins include a second cytoplasmic effector function signaling domain. The invention further relates to expression cassettes containing the nucleic acids encoding the novel chimeric receptors, to host cells expressing the novel chimeric receptors and to methods of using the receptors to co-stimulate effector functions in the cells and for using cells expressing the receptors for treatment of cancer, disease and viral infections.

Claims

1. A DNA encoding a chimeric membrane-bound protein, said protein comprising in the N-terminal to C-terminal direction:

a signal sequence;

an extracellular binding domain of a surface membrane or secreted protein that binds specifically to at least one ligand;

a transmembrane domain; and

a cytoplasmic domain of CD2 or CD28;

wherein said extracellular domain is not obtained from CD2 or CD28, and when said DNA is placed in a selected host cell under conditions suitable for expression, said chimeric membrane-bound protein is expressed and co-stimulates effector function signaling in said host cell upon binding of a ligand to the extracellular domain.

2. The DNA according to claim 1 wherein said extracellular domain is from a cell differentiation antigen.

3. The DNA according to claim 2 wherein said extracellular domain is from CD4.

4. The DNA according to claim 2 wherein said extracellular domain is from CD8.

5. The DNA according to claim 1 wherein said extracellular domain is from an antibody or single-chain antibody or portions or modifications thereof containing ligand binding activity.

6. The DNA according to claim 5 wherein said antibody or single-chain antibody recognizes an antigen selected from the group consisting of viral antigens and tumor cell associated antigens.

7. The DNA according to claim 1 wherein said DNA encoding the cytoplasmic domain further comprises a DNA encoding a cytoplasmic effector function signaling domain that transduces an effector function signal in a host cell upon binding of a ligand to the extracellular domain.

8. An expression cassette comprising a transcriptional initiation region, a DNA according to claim 1 under the transcriptional control of said transcriptional initiation region and a transcriptional termination region.

9. A cell comprising a DNA according to claim 1.

10. A cell comprising a DNA that encodes a chimeric effector function receptor comprising an extracellular ligand-binding domain, a transmembrane domain and a cytoplasmic effector function signaling domain, and a second DNA according to claim 1.

21. The cell according to any one of claims 9, 10, 14, 15, 17 and 20 wherein said cell is a mammalian cell.

22. The cell according to any one of claims 9, 10, 14, 15, 17 and 20 wherein said cell is a human cell.

11. A DNA encoding a hybrid chimeric membrane-bound protein, said protein comprising in the N-terminal to C-terminal direction;

a signal sequence;

an extracellular binding domain of a surface membrane or secreted protein that binds specifically to at least one ligand;

a transmembrane domain;

a cytoplasmic domain of CD2 or CD28; and

a cytoplasmic effector function signaling domain;

wherein said extracellular domain is not obtained from CD2 or CD28, and when said DNA is placed in a selected host cell under conditions suitable for expression, said hybrid chimeric membrane-bound protein is expressed and initiates an effector function signal and a co-stimulatory effector function signal upon binding of a ligand to said extracellular domain.

12. The DNA of claim 11 wherein said cytoplasmic effector function signaling domain is selected from the group consisting of the cytoplasmic effector function signaling domains CD3 zeta chain, the CD3 eta chain, the CD3 gamma chain, the CD3 delta chain, the CD3 epsilon chain, the beta chain of the Fcε

R1 receptor, the gamma chain of the Fcε

R1 receptor, the B29 (Ig beta) chain of the B cell receptor, and a tyrosine kinase.

13. An expression cassette comprising a transcriptional initiation region, a DNA according to claim 11 under the transcriptional control of said transcriptional initiation region and a transcriptional termination region.

14. A cell comprising a DNA according to claim 11.

15. A cell comprising a DNA that encodes a chimeric effector function receptor comprising an extracellular ligand-binding domain, a transmembrane domain and a cytoplasmic effector function signaling domain, and a second DNA according to claim 11.

16. A DNA encoding a hybrid chimeric membrane-bound protein, said protein comprising in the N-terminal to C-terminal direction;

a signal sequence;

an extracellular binding domain of a surface membrane or secreted protein that binds specifically to at least one ligand;

a transmembrane domain;

a cytoplasmic effector function signaling domain; and

a cytoplasmic domain of CD2 or CD28;

wherein said extracellular domain is not obtained from CD2 or CD28, and when said DNA is placed in a selected host cell under conditions suitable for expression, said hybrid chimeric membrane-bound protein initiates an effector function signal and a co-stimulatory effector function signal upon binding of a ligand to said extracellular domain.

17. The DNA of claim 16 wherein said cytoplasmic effector function signaling domain is selected from the group consisting of the cytoplasmic effector function signaling domains of the CD3 zeta chain, the CD3 eta chain, the CD3 gamma chain, the CD delta chain, the CD3 epsilon chain, the beta chain of the Fcγ

R1 receptor, the B29 (Ig beta) chain of the B cell receptor, and a tyrosine kinase.

18. An expression cassette comprising a transcriptional initiation region, a DNA according to claim 16 under the transcriptional control of said transcriptional initiation region and a transcriptional termination region.

19. A cell comprising a DNA according to claim 16.

20. A cell comprising a DNA that encodes a chimeric effector function receptor comprising an extracellular ligand-binding domain, a transmembrane domain and a cytopasmic effector function signaling domain, and a second DNA according to claim 16.

23. A chimeric co-stimulatory receptor protein comprising in the N-terminal to C-terminal direction;

an extracellular ligand binding domain that binds specifically to at least one ligand;

a transmembrane domain; and

a cytoplasmic co-stimulatory signaling domain of CD2 or CD28;

wherein said extracellular domain is not obtained from CD2 or CD28, and when said chimeric co-stimulatory protein is expressed as a membrane-bound receptor in a host cell under conditions suitable for expression said membrane-bound receptor initiates a co-stimulatory effector function signal in said host cell upon binding of a ligand to the extracellular domain.

24. A hybrid chimeric co-stimulatory receptor protein comprising in the N-terminal to C-terminal direction;

an extracellular ligand binding domain that binds specifically to at least one ligand;

a transmembrane domain;

a cytoplasmic co-stimulatory signaling domain of CD2 or CD28; and

a cytoplasmic effector function signaling domain,

wherein said extracellular domain is not obtained from CD2 or CD28, and when said hybrid chimeric co-stimulatory protein is expressed as a membrane-bound receptor in a host cell under conditions suitable for expression, said membrane-bound receptor initiates an effector function signal and a co-stimulatory effector function signal in said host cell upon binding of a ligand to the extracellular domain.

25. A hybrid chimeric co-stimulatory receptor protein comprising in the N-terminal to C-terminal direction;

an extracellular ligand binding domain that binds specifically to at least one ligand;

a transmembrane domain;

a cytoplasmic effector function signaling domain; and

a cytoplasmic co-stimulatory signaling domain of CD2 or CD28;

wherein said extracellular domain is not obtained from CD2 or CD28, and when said hybrid chimeric co-stimulatory protein is expressed as a membrane-bound receptor in a host cell under conditions suitable for expression said membrane-bound receptor initiates an effector function signal and a co-stimulatory effector function signal in said host cell upon binding of a ligand to the extracellular domain.